MARKET

CARA

CARA

Cara
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.35
-0.91
-4.72%
After Hours: 18.35 0 0.00% 16:41 02/26 EST
OPEN
19.69
PREV CLOSE
19.26
HIGH
19.96
LOW
18.34
VOLUME
644.58K
TURNOVER
--
52 WEEK HIGH
22.60
52 WEEK LOW
8.88
MARKET CAP
913.92M
P/E (TTM)
-8.6554
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
10-K: CARA THERAPEUTICS, INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 1d ago
Cara Therapeutics Expects Cash and Cash Equivalents and Available-For-Sale Marketable Securities Sufficient to Fund Ops Into 2023 >CARA
Cara Therapeutics Expects Cash and Cash Equivalents and Available-For-Sale Marketable Securities Sufficient to Fund Ops Into 2023 >CARA
Dow Jones · 1d ago
Cara Therapeutics Sees Top-line Data From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA in AD Patients in 1H
Cara Therapeutics Sees Top-line Data From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA in AD Patients in 1H
Dow Jones · 1d ago
Cara Therapeutics: FDA Accepts NDA Filing for KORSUVA Injection in CKD-aP >CARA
Cara Therapeutics: FDA Accepts NDA Filing for KORSUVA Injection in CKD-aP >CARA
Dow Jones · 1d ago
Cara Therapeutics Q4 EPS $1.59 May Not Compare To $0.36 Estimate, Sales $112.09M May Not Compare To $48.63M Estimate
Cara Therapeutics (NASDAQ:CARA) reported quarterly earnings of $1.59 per share which beat the analyst consensus estimate of $0.36 by 341.67 percent. This is a 360.66 percent increase over losses of $(0.61) per share from
Benzinga · 1d ago
Cara Therapeutics EPS beats by $1.11, beats on revenue
Cara Therapeutics (CARA): Q4 GAAP EPS of $1.59 beats by $1.11.Revenue of $112.1M (+2391.1% Y/Y) beats by $63.47M.Based on timing expectations and projected costs for current clinical development plans, Cara
Seekingalpha · 1d ago
Press Release: Cara Therapeutics Reports Fourth -2-
Dow Jones · 1d ago
Cara Therapeutics 4Q Rev $112.1M >CARA
Cara Therapeutics 4Q Rev $112.1M >CARA
Dow Jones · 1d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CARA. Analyze the recent business situations of Cara through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CARA stock price target is 34.88 with a high estimate of 47.00 and a low estimate of 21.00.
EPS
Institutional Holdings
Institutions: 253
Institutional Holdings: 33.52M
% Owned: 67.27%
Shares Outstanding: 49.83M
TypeInstitutionsShares
Increased
45
1.81M
New
46
-62.25K
Decreased
48
2.46M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.41%
Pharmaceuticals & Medical Research
-0.83%
Key Executives
President/Chief Executive Officer/Director
Derek Chalmers
Chief Financial Officer
Thomas Reilly
Senior Vice President/Chief Scientific Officer
Frederique Menzaghi
Chief Compliance Officer/General Counsel/Secretary
Scott Terrillion
Vice President/Controller
Richard Makara
Other
Joana Goncalves
Lead Director/Independent Director
Martin Vogelbaum
Director
Susan Shiff
Independent Director
Harrison Bains
Independent Director
Jeffrey Ives
Independent Director
Christopher Posner
  • Dividends
  • Splits
  • Insider Activity
No Data
About CARA
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.

Webull offers kinds of Cara Therapeutics Inc stock information, including NASDAQ:CARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CARA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CARA stock methods without spending real money on the virtual paper trading platform.